Humans have known for centuries that copper is a potent weapon against infection. New research shows that the bacteria that cause serious urinary tract infections “know” this, too, and steal copper to prevent the metal from being used against them.
Blocking this thievery with a drug may significantly improve patients’ chances of fighting off infections, according to researchers at Washington University School of Medicine in St. Louis. The findings appear online July 8 in Nature Chemical Biology.
In the United States alone, annual treatment costs for urinary tract infections are estimated to run as high as $1.6 billion. Most urinary tract infections are caused by Escherichia coli (E. coli).
“While some patients are able to clear these infections without issue, the infection persists in others or recurs despite antibiotic therapy,” says senior author Jeff Henderson, MD, PhD, assistant professor of medicine and of molecular microbiology. “In some cases, the infection spreads to the kidney or the blood and becomes life-threatening. We’ve been investigating what’s different about the bacteria that cause these more troublesome infections.”
Scientists have known for years that E. coli makes a molecule called yersiniabactin that takes iron from host cells. The bacteria need the iron to grow and reproduce.
In earlier research, Henderson found that the E. coli that cause serious infections are more likely to make yersiniabactin. This finding and the fact that E. coli already produce another molecule that steals iron led Henderson and Kaveri Chaturvedi, a student in his laboratory, to suspect that the bacterium might be using yersiniabactin for other purposes.
To test the theory, the researchers put yersiniabactin in urine samples from healthy patients. They found the molecule bound iron as expected, but also picked up copper. Next, they conducted the same analysis in samples from patients with urinary tract infections who were treated at the University of Washington in Seattle.
“We found copper bound to yersiniabactin in nearly every patient whose bacteria made the molecule,” Henderson says. “Yersiniabactin was often bound to copper more than it was to iron.”
When researchers put E. coli in the same test tube with copper, the bacteria that made yersiniabactin were more likely to survive.
Copper’s microbe-fighting properties were recognized long before scientists had described the microbes that cause infection. Ancient Greeks and Egyptians knew that treating wounds with copper improved the healing process.
Modern researchers have two explanations for copper’s anti-microbial effects: the metal can stimulate production of other chemically reactive molecules that damage bacteria; and it also is directly toxic to the bacteria.
Henderson, who treats patients with urinary tract infections at Barnes-Jewish Hospital, is currently studying whether the presence or absence of yersiniabactin can help physicians assess an infection’s chances of becoming more serious.
He and his colleagues are also looking at other disease-causing bacteria that make yersiniabactin to see if they use it in a fashion similar to the E. coli that cause urinary tract infections.
Chaturvedi KS, Hung CS, Crowley JR, Stapleton AE,
Henderson JP. The siderophore yersiniabactin bids copper to protect
pathogens during infection. Nature Chemical Biology, July 8, 2012.
Funding from the Burroughs-Wellcome Fund and the National Institutes of Health (K12 HD001459-09, AI 07172, HL101263, DK64540, DK082315, RR024992, RR00954, GM103422-35, DK20579 and DK56341) supported this research.
Washington University School of Medicine’s 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is one of the leading medical research, teaching and patient care institutions in the nation, currently ranked sixth in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.